Breaking News
Investing Pro 0
Close

Bluebird bio Inc (BLUE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Bluebird's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.71 +0.04    +0.68%
10:43:31 - Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 412,141
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 6.60 - 6.74
Bluebird 6.71 +0.04 +0.68%

BLUE Candlestick Patterns

 
Dozens of bullish and bearish live candlestick chart patterns for the Bluebird bio Inc stock and use them to predict future market behavior. The Bluebird stock patterns are available in a variety of time frames for both long and short term investments. Gain a trading edge with the auto pattern recognition feature and gain an insight into what the patterns mean.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Customize

Candlestick Patterns

Time Frame
Pattern Indication
Type
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Deliberation Bearish 1H Current
Doji Star Bearish 1H Current
Completed Patterns
Three Inside Up 1W 1 Jan 29, 2023
Deliberation Bearish 1D 1 Feb 06, 2023
Doji Star Bearish 1D 1 Feb 06, 2023
Three Outside Up 1H 1 Feb 07, 2023 09:00AM
Engulfing Bearish 30 1 Feb 07, 2023 10:00AM
Upside Gap Three Methods 30 1 Feb 07, 2023 10:00AM
Three Black Crows 15 1 Feb 07, 2023 10:15AM
Harami Bullish 1W 2 Jan 22, 2023
Harami Cross 1W 2 Jan 22, 2023
Bullish Engulfing 1H 2 Feb 06, 2023 03:00PM
Three Outside Up 30 2 Feb 07, 2023 09:30AM
Evening Doji Star 1W 3 Jan 15, 2023
Evening Doji Star 5H 3 Feb 06, 2023 09:00AM
Belt Hold Bullish 30 3 Feb 06, 2023 03:30PM
Bullish Engulfing 30 3 Feb 06, 2023 03:30PM
Doji Star Bearish 1W 4 Jan 08, 2023
Doji Star Bearish 5H 4 Feb 03, 2023 11:00AM
Advance Block Bearish 1H 5 Feb 06, 2023 12:00PM
Deliberation Bearish 1H 5 Feb 06, 2023 12:00PM
Three Outside Up 15 5 Feb 06, 2023 03:45PM
Belt Hold Bullish 15 6 Feb 06, 2023 03:30PM
Bullish Engulfing 15 6 Feb 06, 2023 03:30PM
Harami Bearish 1M 7 Jul 22
Harami Cross Bearish 1M 7 Jul 22
Belt Hold Bullish 30 7 Feb 06, 2023 01:30PM
Bullish Engulfing 30 7 Feb 06, 2023 01:30PM
Stick Sandwich 15 8 Feb 06, 2023 03:00PM
Engulfing Bearish 1W 9 Dec 04, 2022
Engulfing Bearish 30 10 Feb 06, 2023 12:00PM
Upside Gap Three Methods 30 10 Feb 06, 2023 12:00PM
Advance Block Bearish 30 11 Feb 06, 2023 11:30AM
Belt Hold Bearish 15 11 Feb 06, 2023 02:15PM
Engulfing Bearish 15 11 Feb 06, 2023 02:15PM
Separating Lines Bullish 15 12 Feb 06, 2023 02:00PM
Bullish doji Star 1M 14 Dec 21
Three Black Crows 1D 14 Jan 18, 2023
Bullish Hammer 5H 14 Jan 30, 2023 07:00AM
Bullish doji Star 15 14 Feb 06, 2023 01:30PM
Belt Hold Bearish 15 15 Feb 06, 2023 01:15PM
Falling Three Methods 1M 19 Jul 21
Dark Cloud Cover 1H 22 Feb 02, 2023 09:00AM
Engulfing Bearish 5H 25 Jan 23, 2023 05:00AM
Upside Gap Three Methods 5H 25 Jan 23, 2023 05:00AM
Downside Gap Three Methods 1D 26 Dec 29, 2022
Inverted Hammer 5H 28 Jan 19, 2023 11:00AM
Inverted Hammer 15 29 Feb 06, 2023 09:45AM
Thrusting Bearish 5H 35 Jan 13, 2023 03:00PM
Falling Three Methods 1M 36 Feb 20
Harami Cross 1W 37 May 22, 2022
Belt Hold Bearish 1D 37 Dec 13, 2022
Morning Doji Star 1M 38 Dec 19
Engulfing Bearish 15 38 Feb 03, 2023 02:00PM
Bullish doji Star 1M 39 Nov 19
Inverted Hammer 1W 40 May 01, 2022
Harami Bullish 15 41 Feb 03, 2023 01:15PM
Harami Cross 15 41 Feb 03, 2023 01:15PM
Evening Doji Star 1D 45 Dec 01, 2022
Engulfing Bearish 1D 45 Dec 01, 2022
Engulfing Bearish 1M 46 Apr 19
Doji Star Bearish 1D 46 Nov 30, 2022
Deliberation Bearish 1M 47 Mar 19
Doji Star Bearish 1M 47 Mar 19
Three Outside Up 1M 48 Feb 19
Inverted Hammer 1W 48 Mar 06, 2022
Bullish Engulfing 1M 49 Jan 19
Three Inside Up 1H 51 Jan 26, 2023 03:00PM
Three Outside Down 5H 52 Jan 03, 2023 03:00PM
Three Black Crows 30 52 Feb 01, 2023 10:30AM
Engulfing Bearish 5H 53 Jan 03, 2023 10:00AM
Bullish Engulfing 1M 54 Aug 18
Bullish doji Star 1D 54 Nov 17, 2022
Dragonfly Doji 1D 54 Nov 17, 2022
Bullish doji Star 1M 55 Jul 18
Inverted Hammer 15 55 Feb 03, 2023 09:45AM
Bullish Engulfing 1M 57 May 18
Morning Doji Star 1M 57 May 18
Advance Block Bearish 5H 57 Dec 29, 2022 03:00PM
Bullish doji Star 1M 58 Apr 18
Three Inside Up 5H 59 Dec 29, 2022 05:00AM
Falling Three Methods 30 59 Jan 31, 2023 01:30PM
Harami Bullish 5H 60 Dec 28, 2022 02:00PM
Harami Cross 5H 60 Dec 28, 2022 02:00PM
Advance Block Bearish 1H 61 Jan 25, 2023 12:00PM
Doji Star Bearish 1M 62 Dec 17
Three Black Crows 15 62 Feb 02, 2023 02:30PM
Advance Block Bearish 1M 64 Oct 17
Harami Cross Bearish 30 64 Jan 31, 2023 11:00AM
Advance Block Bearish 30 65 Jan 31, 2023 10:30AM
Doji Star Bearish 1H 66 Jan 24, 2023 02:00PM
Harami Cross Bearish 1H 66 Jan 24, 2023 02:00PM
Stick Sandwich 15 66 Feb 02, 2023 01:30PM
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

BLUE Comments

Write your thoughts about Bluebird bio Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Giancarlo Grosso
Giancarlo Grosso Oct 04, 2022 1:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy - GlobeNewswireReal Endpoints, the leading market-access platform and advisory firm, announced a collaboration with bluebird bio, inc., to provide multiple health plans with access to an innovative,
Johny Cash
Johny Cash Jul 31, 2022 3:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
will it go up?
Theodore Striker
Theodore Striker Jul 31, 2022 3:46PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
yes
Gaetano Ciancaglini
Gattomao Dec 21, 2021 10:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Slite brease...finally going UP like a Kite!!!
Ra Pa
Ra Pa Nov 08, 2021 10:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
falling like a little stone down a chasm
Bm Bendary
Bm Bendary Nov 05, 2021 9:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The stock appears here at Investing.com gaining .2% at 16.4 usd?
Bm Bendary
Bm Bendary Nov 05, 2021 9:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
As if yesterday closing was 16:30!
Ra Pa
Ra Pa Nov 05, 2021 7:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why so much down again?
John Brand
John Brand Nov 05, 2021 7:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
TSVT tax-free dividend distribution
Ra Pa
Ra Pa Nov 05, 2021 7:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ok thanks, any value left on this or should we sell the old stock?
Eduardo Camillo
Eduardo Camillo Oct 23, 2021 3:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dear bluebird bio, Inc. Stockholder:In January 2021, we announced a transformative milestone for bluebird bio, Inc.—our intent to separate our oncology portfolio and programs from our severe genetic disease portfolio and programs, thereby creating two independent, publicly traded companies. The strategic objectives of the separation are to unlock value, enhance operational performance and strategic flexibility and tailor the capital structures to best serve these distinct businesses.We believe the best way to realize the full potential of this separation is for bluebird bio, Inc. and 2seventy bio, Inc. to operate independently, with distinct management teams and boards of directors dedicated to their unique business strategies. Through this separation, we have the potential to create two focused, durable businesses that are well-positioned with the resources, talent and foundation to be industry leaders in their respective fields.Going forward, bluebird bio, Inc. intends to focus primarily on its programs in severe genetic disease, including betibeglogene autotemcel (beti-cel; formerly LentiGlobin gene therapy for β-thalassemia), LentiGlobin gene therapy for sickle cell disease, and elivaldogene autotemcel (eli-cel; formerly Lenti-D gene therapy for cerebral adrenoleukodystrophy). 2seventy bio, Inc. plans to focus primarily on the discovery and development of novel engineered cell therapies for cancer, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. 2seventy bio, Inc. expects to commercialize idecabtagene vicleucel (ide-cel; being commercialized as Abecma) in the United States and develop bb21217 through its collaboration arrangement with Bristol-Myers Squibb.Upon completion of the separation, 2seventy bio, Inc. will be spun out of bluebird bio, Inc. and established as an independent, publicly traded company. The separation is anticipated to be generally tax-free to bluebird bio, Inc. stockholders. Under the terms of the distribution, each bluebird bio, Inc. stockholder will receive one share of 2seventy bio, Inc. common stock for every three shares of bluebird bio, Inc. common stock held of record on October 19, 2021, the record date for the distribution. You do not need to take any action to receive the common stock of 2seventy bio, Inc. to which you are entitled as a bluebird bio, Inc. stockholder as of the record date.Please read the attached information statement, which is being shared with all bluebird bio, Inc. stockholders as of the record date for the distribution. It describes the separation in detail and contains important information about bluebird bio, Inc. and 2seventy bio, Inc.We thank you for your continued support of bluebird bio, Inc. Sincerely,Daniel S. LynchChairman of the Boardbluebird bio, Inc.
Eduardo Camillo
Eduardo Camillo Oct 23, 2021 3:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dear Future 2seventy bio, Inc. Stockholder:On behalf of the entire future 2seventy bio, Inc. team, I am pleased to welcome you as a future stockholder of our new company.2seventy bio, Inc. will be a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. Its programs will be based on chimeric antigen receptor (CAR) technology and T cell receptor technology. At launch, 2seventy bio, Inc.’s programs will include idecabtagene vicleucel; ide-cel, or Abecma, and bb21217, CAR-T cell product candidates for the treatment of multiple myeloma, which are partnered under a collaboration arrangement with Bristol-Myers Squibb. We believe our team’s expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies will enable us to develop a pipeline of highly innovative, targeted cellular therapies for patients with cancer.Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “TSVT” in connection with the distribution of our company’s common stock by bluebird bio, Inc.I invite you to learn more about 2seventy bio, Inc. by reviewing the enclosed information statement. We look forward to our future as an independent company, and to your support as a 2seventy bio, Inc. stockholder as we begin this new and exciting chapter.Sincerely,Nick LeschlyChief Executive Officer2seventy bio, Inc.
Thierry Maa
Thierry Maa Aug 16, 2021 10:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Falling knife
игорь рудов
игорь рудов Aug 10, 2021 12:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I believe that shareholders and the board of directors should force Nick Leschly to leave. he is not able to manage the company well and make it profitable. this will be well received by investors. this is now one of his few steps that will make the price rise.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email